CAR-T Cells in Treating Patients With Relapsed or Refractory Multiple Myeloma
This study is aimed to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma
Relapsed or Refractory Multiple Myeloma
DRUG: BCMA CAR-T|DRUG: Fludarabine|DRUG: Cyclophosphamide
Number of Participants with Severe/Adverse Events as a Measure of Safety, Number of Participants with Severe/Adverse Events as a Measure of Safety, 28 days|CAR-T Cell expansion level, Copies numbers of CAR in peripheral blood(PB) and/or bone marrow(BM), 24 months
Objective response rate of complete remission and partial remission, Objective response rate of complete remission and partial remission, 24 months|Overall survival time, Overall survival time, 24 months
This is a study to evaluate the safety, feasibility and efficacy of CAR-T cell therapy in the treatment of relapsed or refractory multiple myeloma.

The Main research objectives:

To evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.

The Secondary research objectives:

To evaluate the safety and efficacy of CAR-T cell therapy in patients with relapsed or refractory multiple myeloma.